Table 1.
Baseline clinical characteristics according to HBcAb status in HBsAg-negative DLBCL patients
| Characteristic | HBcAb-negative [cases (%)] | HBcAb-positive [cases (%)] | P value |
|---|---|---|---|
| Total | 110 | 55 | |
| Sex | 0.434 | ||
| Male | 67 (60.9) | 30 (54.5) | |
| Female | 43 (39.1) | 25 (45.5) | |
| ECOG PS | 0.525 | ||
| 0–1 | 96 (87.3) | 46 (83.6) | |
| ≥2 | 14 (12.7) | 9 (16.4) | |
| Bulky mass | 0.619 | ||
| Yes | 28 (25.5) | 16 (29.1) | |
| No | 82 (74.5) | 39 (70.9) | |
| B symptoms | 0.448 | ||
| − | 80 (72.7) | 43 (78.2) | |
| + | 30 (27.3) | 12 (21.8) | |
| Ann Arbor stage† | 0.698 | ||
| I–II | 52 (47.3) | 28 (50.9) | |
| III-IV | 57 (51.8) | 27 (49.1) | |
| Liver involvement | 0.720 | ||
| − | 104 (94.5) | 53 (96.4) | |
| + | 6 (5.5) | 2 (3.6) | |
| IPI score† | 0.851 | ||
| 0–1 | 48 (43.6) | 21 (38.2) | |
| 2 | 28 (25.4) | 17 (30.9) | |
| 3 | 23 (20.9) | 11 (20.0) | |
| 4-5 | 10 (9.1) | 6 (10.9) | |
| ALT | 0.874 | ||
| ≤40 U/L | 95 (86.4) | 47 (85.5) | |
| >40 U/L | 15 (13.6) | 8 (14.5) | |
| AST | 0.863 | ||
| ≤45 U/L | 97 (88.2) | 49 (89.1) | |
| >45 U/L | 13 (11.8) | 6 (10.9) | |
| TB | 0.852 | ||
| ≤20.5 μmol/L | 99 (90.0) | 50 (90.9) | |
| >20.5 μmol/L | 11 (10.0) | 5 (9.1) | |
| LDH | 0.910 | ||
| ≤245 U/mL | 67 (60.9) | 33 (60.0) | |
| >245 U/mL | 43 (39.1) | 22 (40.0) | |
| HBsAb | <0.001 | ||
| – | 82 (74.5) | 3 (5.5) | |
| + | 28 (25.5) | 52 (94.5) | |
| HBeAb | 0.251 | ||
| – | 102 (92.7) | 48 (87.3) | |
| + | 8 (7.3) | 7 (12.7) |
HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, international prognostic index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, total bilirubin; LDH, lactate dehydrogenase; HBsAb, hepatitis B surface antibody; HBeAb, hepatitis B e antibody. †The information of Ann Arbor stage and IPI were available for 164 patients.